<PubmedArticle>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">26753005</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>01</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1758-8340</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2016</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Therapeutic advances in medical oncology</Title>
<ISOAbbreviation>Ther Adv Med Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>48-56</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1758834015616934</ELocationID>
<Abstract>
<AbstractText>Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with advanced BRAFV600 mutated melanoma has shown objective tumor responses in approximately half of the patients. However, the duration of responses is limited in a majority of these patients, with progression-free survival rates around 6 months due to tumor progression from development of acquired resistance. Preclinical studies have suggested that concurrent inhibition of the BRAF kinases and MEK of the mitogen-activated protein kinase (MAPK) pathway could decrease MAPK-driven acquired resistance, resulting in longer duration of responses, higher rate of tumor responses, and a decrease in the cutaneous toxicities observed from paradoxical MAPK pathway activation with BRAF inhibitor monotherapy. This review provides an overview of the currently available clinical trial data on BRAF and MEK inhibitors together and in combinations with other therapeutic agents. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eroglu</LastName>
<ForeName>Zeynep</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Moffitt Cancer Center, Tampa, FL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ribas</LastName>
<ForeName>Antoni</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Division of Hematology-Oncology, UCLA, 11-934 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Ther Adv Med Oncol</MedlineTA>
<NlmUniqueID>101510808</NlmUniqueID>
<ISSNLinking>1758-8340</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">BRAF inhibitors</Keyword>
<Keyword MajorTopicYN="N">MEK inhibitors</Keyword>
<Keyword MajorTopicYN="N">melanoma</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>1</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26753005</ArticleId>
<ArticleId IdType="doi">10.1177/1758834015616934</ArticleId>
<ArticleId IdType="pii">10.1177_1758834015616934</ArticleId>
<ArticleId IdType="pmc">PMC4699264</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>N Engl J Med. 2015 Jan 1;372(1):30-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25399551</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2014 Aug;15(9):954-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25037139</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2014 Feb;50(3):611-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24295639</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Feb 23;366(8):707-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22356324</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2014 Nov 20;32(33):3697-704</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25287827</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jul 12;367 (2):107-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22663011</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2012 Nov;13(11):1087-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23051966</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jan 19;366(3):207-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22256804</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2013 Mar 1;19(5):1225-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23307859</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2002 Jun 27;417(6892):949-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12068308</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2015 Nov 1;121(21):3826-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26218930</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sci Transl Med. 2015 Mar 18;7(279):279ra41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25787767</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2014 Nov 13;371(20):1877-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25265492</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Apr 10;31(11):e173-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23460716</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2015 Aug 1;386(9992):444-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26037941</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Melanoma Res. 2015 Aug;25(4):302-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25933211</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2015 Jun 10;33(17 ):1889-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25667295</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Discov. 2014 Dec;4(12):1377-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25395294</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2013 Oct 15;73(20):6106-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24097822</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2010 Aug 19;363(8):711-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20525992</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Aug 1;29(22):3085-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21383288</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2015 May 13;15:400</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25962795</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2012 May 1;18(9):2502-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22351686</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2012 Mar 1;18(5):1386-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22156613</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pharmacol Exp Ther. 2013 Mar;344(3):655-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23249624</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Feb 1;31(4):482-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23248257</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2015 Feb 9;27(2):240-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25600339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2011 Jun 30;364(26):2507-16</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21639808</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2014 Apr 1;20(7):1965-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24463458</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2012 Jul 28;380(9839):358-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22735384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Discov. 2014 Jan;4(1):80-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24265155</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2014 Nov 13;371(20):1867-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25265494</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Feb 10;31(5):616-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23295794</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Commun. 2014 Dec 02;5:5694</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25452114</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Sep 10;31(26):3205-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23918947</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Nov;367 (18):1694-703</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23020132</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>